Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Akira IWASHIMA"'
Autor:
Satoshi Watanabe, Takeshi Ota, Masachika Hayashi, Hiroyuki Ishikawa, Aya Otsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Takao Miyabayashi, Satoru Miura, Hiroshi Tanaka, Tetsuya Abe, Masaaki Okajima, Masaki Terada, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Toshiaki Kikuchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3070-3077 (2020)
Abstract Background Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) is potentially life‐threatening and is a common reason of the discontinuation of therapy. In contrast, an
Externí odkaz:
https://doaj.org/article/b15f1897c0a94d74af3eab35d56674ed
Autor:
Toshiya Fujisaki, Satoshi Watanabe, Takeshi Ota, Kohei Kushiro, Yusuke Sato, Miho Takahashi, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Satoshi Hokari, Rie Kondo, Takao Miyabayashi, Tetsuya Abe, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Naoya Matsumoto, Takashi Ishida, Akira Iwashima, Kazuhiro Sato, Hirohisa Yoshizawa, Nobumasa Aoki, Masachika Hayashi, Yasuyoshi Ohshima, Toshiyuki Koya, Toshiaki Kikuchi
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
ObjectivesAlthough immune checkpoint inhibitors (ICIs) have been shown to improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients, ICIs sometimes cause various types of immune-related adverse events (irAEs), which lead t
Externí odkaz:
https://doaj.org/article/ecc089bdf85d4930b1e2d948173bc025
Autor:
Yu Saida, Satoshi Watanabe, Tetsuya Abe, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Kenichi Koyama, Satoru Miura, Hiroshi Tanaka, Masaaki Okajima, Masaki Terada, Takashi Ishida, Hiroki Tsukada, Masato Makino, Akira Iwashima, Kazuhiro Sato, Naoya Matsumoto, Hirohisa Yoshizawa, Toshiaki Kikuchi
Publikováno v:
Thoracic Cancer, Vol 10, Iss 11, Pp 2106-2116 (2019)
Background Although the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in EGFR‐mutant non‐small cell lung cancer (NSCLC) patients has been demonstrated, their efficacy in EGFR‐mutant NSCLCs with c
Externí odkaz:
https://doaj.org/article/4c3c0980a21a4b178a904cf7dd6b0608
Autor:
Yosuke Kimura, Ryo Ito, Yoshiki Hayashi, Toshihiro Kazawa, Yoshiro Endo, Akira Iwashima, Yasuyoshi Ohshima, Satoshi Watanabe, Toshiyuki Koya, Toshiaki Kikuchi
Publikováno v:
Respiratory Medicine Case Reports, Vol 33, Iss , Pp 101451- (2021)
A 70-year-old man, treated for asthma for 2 years and chronic sinusitis for several months, presented with fever, numbness in the lower limbs, heaviness in the head, gross hematuria, and black stools. He also had eosinophilia, elevated serum IgG4 lev
Externí odkaz:
https://doaj.org/article/4243e70b3b9249f0a35bda1bf1aff001
Autor:
Satoshi, Shoji, Satoru, Miura, Satoshi, Watanabe, Aya, Ohtsubo, Koichiro, Nozaki, Yu, Saida, Kosuke, Ichikawa, Rie, Kondo, Tomohiro, Tanaka, Kenichi, Koyama, Hiroshi, Tanaka, Masaaki, Okajima, Tetsuya, Abe, Takeshi, Ota, Takashi, Ishida, Masato, Makino, Akira, Iwashima, Kazuhiro, Sato, Naoya, Matsumoto, Hirohisa, Yoshizawa, Toshiaki, Kikuchi
Publikováno v:
Translational Lung Cancer Research. 11:1359-1368
This multicenter, open-label, single-arm phase II study [Niigata Lung Cancer Treatment Group (NLCTG) 1302] was conducted to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy for previously treated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2edbbf63498c552456847e7013c68d58
https://doi.org/10.21037/tlcr-22-89
https://doi.org/10.21037/tlcr-22-89
Autor:
Kodai Kawamura, Hidekazu Matsushima, Hiroshi Sakai, Akira Iwashima, Sukeyuki Nakamura, Tohru Kojima, Shinichi Sasaki, Takehiko Shigenaga, Ichiro Natsume, Takaaki Sasaki, Yoshinobu Ohsaki, Kentaro Iwanaga, Koichi Nishi, Yoichiro Mitsuishi, Hirokazu Taniguchi, Kazuhiro Sato, Mitsugu Yamauchi, Motowo Nakajima, Kazuhisa Takahashi
Publikováno v:
Oncology. 100(11)
Introduction: Cisplatin-based chemotherapy was established in the 1980s, and it has been improved by the development of a short hydration protocol in lung cancer therapy. However, cisplatin-based chemotherapy is still associated with renal toxicity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcd2fd602ae04e4236862afcf9182d0e
https://pubmed.ncbi.nlm.nih.gov/36099876
https://pubmed.ncbi.nlm.nih.gov/36099876
Autor:
Hirohisa Yoshizawa, Naoya Matsumoto, Hiroshi Tanaka, Satoru Miura, Kazuhiko Ito, Masaaki Okajima, Akira Iwashima, Kazuhiro Sato, Takashi Ishida, Masato Makino, Kosuke Ichikawa, Tetsuya Abe, Toshiaki Kikuchi, Satoshi Watanabe
Publikováno v:
Transl Lung Cancer Res
Background Afatinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Many patients treated with afatinib experience skin or gastrointestinal toxicity. However
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f07199b680be61b02d6921574a8d79b
https://doi.org/10.21037/tlcr-20-649
https://doi.org/10.21037/tlcr-20-649
Autor:
Rie Kondo, Satoru Miura, Akira Iwashima, Hiroyuki Ishikawa, Aya Otsubo, Masaaki Okajima, Satoshi Shoji, Satoshi Watanabe, Hiroshi Tanaka, Kazuhiro Sato, Kosuke Ichikawa, Tetsuya Abe, Takashi Ishida, Takao Miyabayashi, Hirohisa Yoshizawa, Masachika Hayashi, Koichiro Nozaki, Masaki Terada, Takeshi Ota, Toshiaki Kikuchi
Publikováno v:
Cancer Medicine, Vol 9, Iss 9, Pp 3070-3077 (2020)
Cancer Medicine
Cancer Medicine
Background Interstitial lung disease (ILD) induced by anti‐programmed‐cell death‐1 (PD‐1) and anti‐PD‐ligand 1 (PD‐L1) is potentially life‐threatening and is a common reason of the discontinuation of therapy. In contrast, an enhanceme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7f858e17034989d1f0ff78120f0c62a
https://doaj.org/article/b15f1897c0a94d74af3eab35d56674ed
https://doaj.org/article/b15f1897c0a94d74af3eab35d56674ed
Autor:
Hiroshi Tanaka, Yusuke Sato, Masaaki Okajima, Koichiro Nozaki, Takeshi Ota, Toshiya Fujisaki, Masaki Terada, Toshiaki Kikuchi, Naoya Matsumoto, Satoshi Watanabe, Aya Ohtsubo, Rie Kondo, Takashi Ishida, Satoshi Shoji, Satoru Miura, Akira Iwashima, Masachika Hayashi, Takao Miyabayashi, Miho Takahashi, Kohei Kushiro, Satoshi Hokari, Hirohisa Yoshizawa, Toshiyuki Koya, Kosuke Ichikawa, Nobumasa Aoki, Tetsuya Abe, Kazuhiro Sato, Yasuyoshi Ohshima
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
ObjectivesAlthough immune checkpoint inhibitors (ICIs) have been shown to improve overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients, ICIs sometimes cause various types of immune-related adverse events (irAEs), which lead t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773d59de452ef420169ce75500dec6f1
https://www.frontiersin.org/articles/10.3389/fonc.2021.704475/full
https://www.frontiersin.org/articles/10.3389/fonc.2021.704475/full
Autor:
Toshiya Fujisaki, Yusuke Sato, Akira Iwashima, Masaaki Okajima, Hiroshi Tanaka, Satoshi Hokari, Kazuhiro Sato, Toshiaki Kikuchi, Kosuke Ichikawa, Satoshi Shoji, Miho Takahashi, Hiroyuki Ishikawa, Yasuyoshi Ohshima, Satoru Miura, Toshiyuki Koya, Takao Miyabayashi, Hirohisa Yoshizawa, Nobumasa Aoki, Masaki Terada, Aya Ohtsubo, Takashi Ishida, Kohei Kushiro, Tetsuya Abe, Masachika Hayashi, Satoshi Watanabe, Koichiro Nozaki, Takeshi Ota, Rie Kondo
Publikováno v:
Transl Lung Cancer Res
Background Although immune checkpoint inhibitors (ICIs) are effective for advanced non-small cell lung cancer (NSCLC), ICIs may cause interstitial lung disease (ILD), which results in treatment discontinuation and is sometimes fatal. Despite the high
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb9f4e2648d85fba0c79333e3c4907f2
https://pubmed.ncbi.nlm.nih.gov/34430353
https://pubmed.ncbi.nlm.nih.gov/34430353